Genflow Biosciences reports that its longevity-related patent application has progressed to the national examination phase at the Japanese Patent Office.
The application, entitled “Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases,” was initially submitted on 13 May 2022.
It is jointly owned by the University of Rochester, the Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, with Genflow holding the exclusive license to this intellectual property.
The IP encompasses novel SIRT6 gene variants crucial to genomic stability, metabolic regulation, and healthy ageing. These variants form the foundation of Genflow’s core therapeutic platform and represent a significant component of its pipeline targeting age-related diseases.
“We are pleased to see continued momentum in the protection of our SIRT6 intellectual property,” said Dr. Eric Leire, CEO of Genflow Biosciences.
“Japan represents a strategically important jurisdiction for Genflow, and advancing this patent application strengthens our global positioning as a leader in longevity gene therapy.”
Today’s news follows the recently announced launch of a development programme to explore SIRT6 in eyecare and a partnership with Heureka Labs, a technology spin-off from Duke University, to utilise Heureka’s AI-powered platform to analyse genomic data.